In the company’s news yesterday,
Chembio Diagnostics, Inc. (CEMI.OB) announced that the company has received approval from the United States Food and Drug Administration to extend the testing age range for its HIV rapid point-of-care tests to individuals 13 years of age and older.
A recent clinical study was designed to evaluate the performance of the company’s FDA-approved rapid tests, Clearview® COMPLETE HIV 1/ 2 and Clearview® HIV 1/ 2 STAT-PAK®. The University of Maryland School of Medicine performed the study for Chembio on four separate specimen matrices from each study participant: finger stick capillary whole blood, venous whole blood, serum and plasma. Based upon the results of the studies and other related information provided to the FDA, the PMA supplement was approved to expand the indications-of-use section to include the pediatric sub-population, 13 to 17 years of age.
Of the more than 1 million adults and adolescents estimated to be living with HIV infection in the United States, approximately 21 percent are unaware of their infection. Lowering the testing age from 18 years of age to 13 is consistent with the latest U.S. Centers for Disease Control (CDC) recommendations that routine screening for HIV be performed on all patients 13 to 64 years of age. From a public health perspective, the shift in the CDC recommendations from risk-based to routine “opt-out” testing is anticipated to lower the rate of new HIV infections.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
